|
 Lilly, along with other major insulin makers, Sanofi SA and Novo
Nordisk, has been under mounting pressure from patients and
politicians over the rising cost of the life-sustaining diabetes
treatment.
"While it's still a proposal, we see this as ... a win for patients,
lowering their out-of-pocket costs at the pharmacy counter with the
greatest benefit realized by patients taking more highly-rebated
products such as insulin," Chief Executive David Ricks said on a
call with analysts.
Drugmakers argue they have to keep prices high because of the
rebates they must pay to pharmacy benefit managers and health
insurers to get products on their lists of covered drugs. In
January, the administration of U.S. President Donald Trump proposed
a rule that would end the rebate system or pass along the savings to
patients.
"We'll adapt to whatever rules come out and how they get finalized,”
Ricks said.
Lilly on Wednesday also cut its 2019 profit and revenue forecasts to
account for disappearing sales of its cancer drug Lartruvo, which
won conditional U.S. approval in 2016 based on early data but last
month failed to extend patient survival a confirmatory trial. Costs
related to Lilly's pending $8 billion acquisition of Loxo Oncology
also contributed to the revised forecast.
Lilly has said it is suspending promotion of Lartruvo and it will no
longer be prescribe to new U.S. patients.
[to top of second column] |
The Indianapolis-based drugmaker's research and development spending
is also expected to rise as it develops Loxo's pipeline of targeted
drugs for cancers driven by rare genetic mutations.
The company said it now expects 2019 adjusted earnings of $5.55 to
$5.65 per share, down from its prior forecast of $5.90 to $6.00. It
expects revenue of $25.1 billion to $25.6 billion versus its prior
view of $25.3 billion to $25.8 billion.
"The forecast cut was generally expected, given the Loxo acquisition
and the Lartruvo failure were known events," Edward Jones analyst
Ashtyn Evans said.
"Diabetes will always be an area where we'll see pricing pressure.
Lilly fully takes that into consideration when giving guidance," she
added.
Excluding items, Lilly earned $1.33 per share, a penny shy of
analysts' average estimate, according to IBES data from Refinitiv.
Eli Lilly shares fell 1.3 percent to $118.82.
(Reporting by Manogna Maddipatla, Tamara Mathias in Bengaluru and
Julie Steenhuysen in Chicago; Editing by Saumyadeb Chakrabarty and
Bill Berkrot)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
